Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PK of Nitazoxanide in Hepatic Impairment
NCT05116826Phase 1Completed
- Sponsor
- Genfit
- Start
- Nov 2021
- Primary completion
- Apr 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of nitazoxanide in liver failure (3 arms), sponsored by Genfit. Primary endpoints: Area under the plasma concentration time curve from time zero to 12h, Area under the plasma concentration time curve from time zero to last quantifiable concentration at Day 7 and 1 more. Started Nov 2021; status: completed.
02
Drugs
nitazoxanide
03
Conditions
liver failure
Beyond the preview
Go deeper on NCT05116826.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05116826.